SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 225.75 millions for the March 2025 quarter. The mentioned figure indicates a decline of about -37.96% as against Rs. 363.86 millions during the year-ago period.The Net Loss for the quarter ended March 2025 is Rs. -44.17 millions as compared to Net Profit of Rs. 55.13 millions of corresponding quarter ended March 2024 Operating profit Margin for the quarter ended March 2025 improved to 16.71% as compared to -214.55% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 225.75 363.86 -37.96 1036.04 1367.97 -24.26 1036.04 1367.97 -24.26
Other Income 41.52 73.69 -43.66 41.85 95.72 -56.28 41.85 95.72 -56.28
PBIDT 16.71 -214.55 -107.79 -103.34 -240.68 -57.06 -103.34 -240.68 -57.06
Interest 14.76 -336.91 -104.38 25.31 19.04 32.93 25.31 19.04 32.93
PBDT 1.95 122.36 -98.41 -128.65 -259.72 -50.47 -128.65 -259.72 -50.47
Depreciation 46.12 49.55 -6.92 186.31 184.10 1.20 186.31 184.10 1.20
PBT -44.17 72.81 -160.66 -314.96 -443.82 -29.03 -314.96 -443.82 -29.03
TAX 0.00 17.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 17.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -44.17 55.13 -180.12 -314.96 -443.82 -29.03 -314.96 -443.82 -29.03
Equity 165.83 165.83 0.00 165.83 165.83 0.00 165.83 165.83 0.00
PBIDTM(%) 7.40 -58.96 -112.55 -9.97 -17.59 -43.31 -9.97 -17.59 -43.31

Vivimed Labs Share Price

7.42 0.01 (0.13%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×